Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

About Fexlamose Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve lung function, lessen symptoms and improve quality of life.

MRI of inhaled perfluoropropane can assess regional lung ventilation and monitor improvements in response to medication ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing drugs, according to a new study.

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is needed to improve ...

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing drugs, according to a new ...

The study, involving five patients, demonstrated the procedural efficiency and feasibility of AerWave's technology.

Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the ...